Subscribe
Share
Share
Embed
One Pill, a Fifth Door: Caplyta Bids to Treat Bipolar Mania
Johnson & Johnson has asked the FDA to approve Caplyta (lumateperone) for manic and mixed episodes in bipolar I disorder after two Phase 3 trials met their endpoints, which would make it the drug's fifth approved adult use.
Source
Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication — Johnson & Johnson, November 19, 2026
Mental Health & Addiction Recovery News.